Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086125 · ClinicalTrials.gov registry record · Phase 2
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase 2 study of Lymphoma and Leukemia, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 8
- Study locations
NCT00086125 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 57 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT00086125, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.
Conditions Studied
Interventions
- DRUG ridaforolimus
Study Locations (8)
Illinois
- University of Chicago Hospitals, Section of Hematology/Oncology - Chicago
Missouri
- Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place - St Louis
New Jersey
- The Cancer Institute of New Jersey - New Brunswick
New York
- New York Presbyterian Hospital, Weill College of Cornell University - New York
North Carolina
- Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic - Durham
Ohio
- Gabrail Cancer Center - Canton
Pennsylvania
- Jeane's Hospital of TUHS - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086125
The ClinicalTrials.gov registry entry for NCT00086125 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which ridaforolimus is the first listed.
NCT00086125 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Illinois, Missouri, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00086125 about?
NCT00086125 is a clinical study titled "Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)". The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.
What is the current status of trial NCT00086125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2004-06. Estimated completion is 2006-06.
What conditions does trial NCT00086125 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Hematologic Malignancies, Myeloid Metaplasia.
What interventions are being tested in trial NCT00086125?
The interventions under investigation include: ridaforolimus (DRUG).
Who is sponsoring clinical trial NCT00086125?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00086125 being conducted?
This trial has 8 study locations across Illinois, Missouri, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.